A phage-therapy roadmap arrives before strong clinical evidence
A Nature Medicine consensus document sets out more than 60 recommendations for personalized phage therapy, from selection and preparation to monitoring. It can make care and reporting more comparable, but the document says evidence on efficacy and some doses remains limited.
Science··Evening
A shared route
Personalized phage therapy uses viruses selected against disease-causing bacteria for an individual patient. The new guideline lays out more than 60 recommendations across selection, pharmacy preparation, quality control, administration and monitoring. It was developed with professional societies, patient representatives, regulators and international experts, placing those practical steps in one shared record. It does not prescribe one universal product; it organizes choices around each case.[1]
What it standardizes
The document addresses underlying facilities, medicine preparation, product checks, clinical delivery and future research needs. A common description of the product, its preparation and its monitoring can make records from different centres easier to compare. The organizational gain is comparability of care delivery, whereas a change in a patient's outcome requires efficacy evidence.[1]
Evidence remains limited
The guideline draws chiefly on laboratory evidence, early clinical testing, specialist judgment and collections of cases. For that reason, it leaves unsettled acceptable standards for product checks and route-specific amounts. The immediate result is a clearer framework for use and monitoring, while stronger clinical evidence is still needed to establish benefit for particular patients and infection settings.[1]
